Recent Posts
- Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics
- Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph
- Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology
- NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
Archives
-
AffiliateLabz says:
-
SEO Referral Program says:
-
White Label SEO says:
Find us on Facebook
Archives
Recent Posts
- Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics
- Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph
- Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology
- NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia
- Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile
Recent Tweets
-
@DoorCountyMom If you require some assistance please submit a ticket here bit.ly/2rbLnxz or send an email… twitter.com/i/web/status/1…
3 hours ago -
@Theme_Fusion talk at the awesome @WPVienna in action 😃 #WCVienna pic.twitter.com/s9vwI7xThM
2 days ago -
Speakers dinner at @WPVienna #wcvie, meeting all the awesome folks organizing or participating. Only a few more hou… twitter.com/i/web/status/1…
3 days ago
Recent Comments